Malignant Male Reproductive System Neoplasm

Malignant Male Reproductive System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

6,225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,451
Recruiting: 784
Ph III recruiting: 82
Growth YoY: +24.4%
Industry share: 18%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 27.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (762)

clinicaltrialsPublishedShowing 1–50 of 63 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07574541	Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance	not yet recruiting	Phase 2	52	National Cancer Institute (NCI)NIH	1	Sep 29, 2026	clinicaltrials
NCT07667400	Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer	not yet recruiting	Phase 1 / Phase 2	120	National Cancer Institute (NCI)NIH